The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10279 malaria professionals are enjoying the free benefits of MalariaWorld today

ferroquine

Inhibitory Activity of Ferroquine, versus Chloroquine, against Western Kenya Plasmodium falciparum Field Isolates Determined by a SYBR Green I In Vitro Assay.

December 9, 2011 - 08:29 -- Patrick Sampao
Author(s): 
Eyase FL, Akala HM, Johnson JD, Walsh DS.
Reference: 
Am J Trop Med Hyg. 2011 Dec;85(6):984-8.

MalariaWorldThese findings support the notion that FQ could be useful in treating persons with P. falciparum malaria.

Country: 
Medical Condition: 
Medical Treatment: 

Ex Vivo Drug Susceptibility of Ferroquine against Chloroquine-Resistant Isolates of Plasmodium falciparum and P. vivax

August 18, 2011 - 15:09 -- Patrick Sampao
Author(s): 
Jutta Marfurt, Ferryanto Chalfein, Ric N. Price, et al.
Reference: 
Antimicrobial Agents and Chemotherapy, September 2011,p. 4461-4464, Vol. 55, No. 9

In the current study, ex vivo FQ activity was tested in multidrug-resistant P. falciparum and P. vivax field isolates using a schizont maturation assay.

Medical Condition: 
Medical Treatment: 

Open Access | Phase I randomized dose-ascending placebo-controlled trials of ferroquine - a candidate anti-malarial drug - in adults with asymptomatic Plasmodium falciparum infection

March 2, 2011 - 11:20 -- Kabogo Ndegwa
Author(s): 
Mombo-Ngoma G, Supan C, Dal-Bianco MP, Missinou MA, Matsiegui P, Ospina Salazar CL, Issifou S, Ter-Minassian D, Ramharter M, Kombila M, Kremsner PG, Lell B
Reference: 
Malaria Journal 2011, 10:53 (1 March 2011)

These phase I trials showed that clinically, ferroquine was generally well-tolerated up to 1,600 mg as single dose and up to 800 mg as repeated dose in asymptomatic young male with P. falciparum infection.

Medical Treatment: 

Synthesis and antimalarial activities of rhenium bioorganometallics based on the 4-aminoquinoline structure

November 3, 2010 - 11:25 -- Kabogo Ndegwa
Author(s): 
Rodrigo Arancibia, Faustine Dubar, Bruno Pradines, Isabelle Forfar, Daniel Dive, A. Hugo Klahn, Christophe Biot
Reference: 
Bioorganic & Medicinal Chemistry Volume 18, Issue 22, 15 November 2010, Pages 8085-8091

A bioorganometallic approach to malaria therapy led to the discovery of ferroquine (FQ, SSR97193). To assess the importance of the electronic properties of the ferrocenyl group, cyclopentadienyltricarbonylrhenium analogues related to FQ, were synthesized.

Medical Condition: 

Plasmodium vivax Susceptibility to Ferroquine

April 20, 2010 - 08:57 -- Kabogo Ndegwa
Author(s): 
M. L. Leimanis, A. Jaidee, K. Sriprawat, S. Kaewpongsri, R. Suwanarusk, M. Barends, A. P. Phyo, B. Russell, L. Renia, and F. Nosten
Reference: 
Antimicrobial Agents and Chemotherapy, May 2010, p. 2228-2230, Vol. 54, No. 5

The novel organometallic chloroquine analog ferroquine (SSR 97193) is effective against chloroquine-resistant Plasmodium falciparum. The ex vivo efficacy of ferroquine against Plasmodium vivax isolates was tested. Ferroquine has a potent ex vivo effect on P. vivax schizont maturation (median 50% inhibitory concentration, 15 nM; n = 42).

Medical Condition: 
Medical Treatment: 
Subscribe to RSS - ferroquine